JPS62145029A - インタ−フエロン組成物 - Google Patents

インタ−フエロン組成物

Info

Publication number
JPS62145029A
JPS62145029A JP61295704A JP29570486A JPS62145029A JP S62145029 A JPS62145029 A JP S62145029A JP 61295704 A JP61295704 A JP 61295704A JP 29570486 A JP29570486 A JP 29570486A JP S62145029 A JPS62145029 A JP S62145029A
Authority
JP
Japan
Prior art keywords
interferon
delta
gamma
combination
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP61295704A
Other languages
English (en)
Japanese (ja)
Inventor
ポール・ジェイソン・レイボウィッツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schering Plough Corp
Original Assignee
Schering Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Corp filed Critical Schering Plough Corp
Publication of JPS62145029A publication Critical patent/JPS62145029A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP61295704A 1985-12-11 1986-12-11 インタ−フエロン組成物 Pending JPS62145029A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/807,887 US4806347A (en) 1985-12-11 1985-12-11 Interferon combinations
US807887 2004-03-24

Publications (1)

Publication Number Publication Date
JPS62145029A true JPS62145029A (ja) 1987-06-29

Family

ID=25197366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61295704A Pending JPS62145029A (ja) 1985-12-11 1986-12-11 インタ−フエロン組成物

Country Status (7)

Country Link
US (1) US4806347A (de)
EP (1) EP0225759B1 (de)
JP (1) JPS62145029A (de)
AT (1) ATE76579T1 (de)
DE (1) DE3685484D1 (de)
ES (1) ES2036526T3 (de)
GR (1) GR3005362T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2039276T3 (es) * 1987-01-20 1993-09-16 Schering Corporation Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
DE60041210D1 (de) 1999-09-17 2009-02-05 Wellstat Biologics Corp Onkolytisches Virus
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20050013801A1 (en) * 2001-10-05 2005-01-20 Hsu Henry H. Methods of treating liver fibrosis and hepatitis c virus infection
WO2004078194A1 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
NZ541951A (en) 2003-03-07 2008-03-28 Robarts Res Inst Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
CA2600675C (en) 2005-03-07 2015-12-15 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998019A (ja) * 1982-10-25 1984-06-06 ジエネンテク，インコ−ポレイテツド インタ−フエロンの相乗効果

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998019A (ja) * 1982-10-25 1984-06-06 ジエネンテク，インコ−ポレイテツド インタ−フエロンの相乗効果

Also Published As

Publication number Publication date
EP0225759A3 (en) 1989-02-08
ATE76579T1 (de) 1992-06-15
GR3005362T3 (de) 1993-05-24
EP0225759B1 (de) 1992-05-27
EP0225759A2 (de) 1987-06-16
DE3685484D1 (de) 1992-07-02
US4806347A (en) 1989-02-21
ES2036526T3 (es) 1993-06-01

Similar Documents

Publication Publication Date Title
DE69330032T2 (de) Therapeutisches kombinationspräparat enthaltend interferon
Fossä et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study
US7670620B2 (en) Topical composition for the treatment of psoriasis and related skin disorders
DE69430440T2 (de) Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten
DE69333321T3 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
JP2888259B2 (ja) インターフェロン−αとヒスタミン、セロトニンまたは相当するレセプター活性を有する物質とを含有するナチュラルキラー細胞（ＮＫ細胞）活性化用製剤
HU206988B (en) Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient
EP0225759B1 (de) Interferon-Zusammensetzungen
AU700502B2 (en) Zwitterionic compositions and methods as biological response modifiers
Northfelt Treatment of Kaposi’s sarcoma: current guidelines and future perspectives
JPH02264730A (ja) Ａｔｌｌ治療用吸入剤
Fischl Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma
JP3631245B2 (ja) ＤＮＡウイルス感染の治療のための薬物の製造のための膜翅類昆虫（ｈｙｍｅｎｏｐｔｅｒａ）毒の使用
US20050003023A1 (en) Topical composition for the treatment of psoriasis and related skin disorders
Ho et al. Paradoxical effects of interferon on reactivation of oral infection with herpes simplex virus after microvascular decompression for trigeminal neuralgia
WO1997014420A1 (en) Treating fibrosis in skeletal muscle tissue
JPH04275231A (ja) 事故結果として多外傷を有する危険な患者に於て、臓器拒絶の予防及び（又は）処置に、スーパーオキシドジスムターゼを使用する方法
Geber et al. Action of naloxone on the interferon-lowering activity of morphine in the mouse
Milligan et al. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis.
US5264208A (en) Potentiation of tumor necrosis factor (TNF) of interferon B1 (IFN-B1) antiviral activities by an anti-cachexia agent
Silver et al. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon.
JP3167763B2 (ja) 創傷治癒促進剤
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
KR970005325B1 (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
IE893828L (en) Treatment of squamous cell carcinoma intralesionally with¹recombinant human alpha interferon